Skip to main content

Table 5 Post chemotherapy treatment (N = 89) Table legend text

From: Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802)

Post chemotherapy

N

%

Irinotecan-based regimen

54

60.7

Oxaliplatin-based regimen

16

18.0

Chemotherapy with bevacizumab

37

41.6

Chemotherapy with cetuximab

32

36.0

Chemotherapy with panitumumab

21

23.6